BIA
TERN

Bell Investment Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Bell Investment Advisors’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$686 Buy
13
+1
+8% +$41 ﹤0.01% 1636
2025
Q4 		$485 Buy
+12
New +$277 ﹤0.01% 1758

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Bell Investment Advisors's TERN Position: Q1 2026 in Review

Bell Investment Advisors increased its Terns Pharmaceuticals (TERN) stake by 8.3% in Q1 2026, buying an estimated $41 and bringing the position to 13 shares worth $686. The position accounts for ﹤0.01% of the portfolio, ranked #1636.

Bell Investment Advisors first reported a position in TERN in Q4 2025 and has held it in 2 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Bell Investment Advisors held 13 shares of Terns Pharmaceuticals worth $686 as of Q1 2026.
  • Bell Investment Advisors bought 1 Terns Pharmaceuticals share in Q1 2026, an estimated $41.
  • Terns Pharmaceuticals made up ﹤0.01% of Bell Investment Advisors's portfolio in Q1 2026, its #1636 holding.
  • Bell Investment Advisors first reported a position in Terns Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Bell Investment Advisors's 13F filing for Q1 2026, filed 17 Apr 2026.